Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will participate in a fireside chat and host one-on-one meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

The pre-recorded fireside chat will be available on the event website prior to the dates of the conference. A replay of the presentation will be available by visiting Veracyte’s website at https://investor.veracyte.com/events-presentations and will remain archived there for approximately 90 days.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Investors and Media Contact:

Tracy Morris

[email protected]

650-380-4413

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Oncology Medical Supplies Medical Devices Health Genetics Biotechnology

MEDIA:

Logo
Logo

Apyx Medical Corporation Announces Approval from FDA to Begin Phase II of U.S. IDE Study

Apyx Medical Corporation Announces Approval from FDA to Begin Phase II of U.S. IDE Study

CLEARWATER, Fla.–(BUSINESS WIRE)–Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced it received approval from the FDA to begin Phase II of its U.S. IDE clinical study evaluating the use of its Renuvion® technology in skin laxity procedures in the neck and submental region.

“We are pleased to announce that the FDA has approved our supplement and we can now move forward with Phase II of our IDE study evaluating the use of our Renuvion® technology for skin laxity procedures in the neck and submental region,” said Charlie Goodwin, President and Chief Executive Officer. “The approved supplement included changes to the treatment protocol based on feedback from study investigators during Phase I of the study, an updated statistical analysis plan and an increase in the number of investigational sites. We expect to begin enrollment of 65 study subjects in early December and plan to update the investment community upon completion of enrollment which we currently target occurring in the third quarter of 2021.”

About Apyx Medical Corporation:

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company’s Helium Plasma Technology is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma® system allows surgeons to operate with a high level of precision while minimizing unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Cautionary Statement on Forward-Looking Statements:

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10-K for the year ended December 31, 2019. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Westwicke Partners on behalf of Apyx Medical Corporation

Mike Piccinino, CFA

investor[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Surgery Medical Devices FDA Hospitals Clinical Trials Biotechnology Other Health Health Pharmaceutical

MEDIA:

Onto Innovation Announces $100 million Share Repurchase Authorization

Onto Innovation Announces $100 million Share Repurchase Authorization

WILMINGTON, Mass.–(BUSINESS WIRE)–
Onto Innovation Inc. (NYSE: ONTO) today announced that its Board of Directors approved a $100 million share repurchase authorization. This authorization replaces the remaining balance of $28 million from the prior repurchase authorization. Repurchases may be made through both public market and private transactions. For the year 2020, approximately 1.9 million shares were cumulatively repurchased for a total value of $52 million. Onto Innovation ended its third fiscal quarter with 49.1 million average diluted shares outstanding.

The new authorization does not obligate Onto Innovation to repurchase any particular amount of common stock during any period and the program may be modified or suspended at any time at the Company’s discretion. Stock repurchases may be made from time to time and the actual amount repurchased will depend on a variety of factors including market conditions.

About Onto Innovation Inc.

Onto Innovation is a leader in process control, combining global scale with an expanded portfolio of leading-edge technologies that include: Un-patterned wafer quality; 3D metrology spanning chip features from nanometer scale transistors to large die interconnects; macro defect inspection of wafers and packages; metal interconnect composition; factory analytics; and lithography for advanced semiconductor packaging. Our breadth of offerings across the entire semiconductor value chain helps our customers solve their most difficult yield, device performance, quality, and reliability issues. Onto Innovation strives to optimize customers’ critical path of progress by making them smarter, faster and more efficient. Headquartered in Wilmington, Massachusetts, Onto Innovation supports customers with a worldwide sales and service organization. Additional information can be found at www.ontoinnovation.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”) which include Rudolph’s expectations about potential uses of our cash and other assets as well as other matters that are not purely historical data. Rudolph wishes to take advantage of the “safe harbor” provided for by the Act and cautions that actual results may differ materially from those projected as a result of various factors, including risks and uncertainties, many of which are beyond Onto Innovation’s control. Such factors include, but are not limited to, market conditions, the possibility that the repurchase program may be suspended or discontinued, and other economic factors. Additional information and considerations regarding the risks faced by Onto Innovation are available in Onto’s Form 10-K report for the year ended December 31, 2019 and other filings with the Securities and Exchange Commission. As the forward-looking statements are based on Onto’s current expectations, the company cannot guarantee any related future results, levels of activity, performance or achievements. Onto Innovation does not assume any obligation to update the forward-looking information contained in this press release.

Source: Onto Innovation Inc.

Michael Sheaffer, +1 978.253.6273

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Technology Semiconductor

MEDIA:

Logo
Logo

Cimpress to Present at the BofA Securities 2020 Leveraged Finance Virtual Conference

Cimpress to Present at the BofA Securities 2020 Leveraged Finance Virtual Conference

DUNDALK, Ireland–(BUSINESS WIRE)–
Cimpress plc (Nasdaq: CMPR) announced today that Sean Quinn, executive vice president and chief financial officer, is scheduled to participate in a fireside chat at the BofA Securities 2020 Leveraged Finance Virtual Conference on Monday, November 30, 2020 at 4:30 p.m. eastern time. A live audio webcast of the presentation will be available at ir.cimpress.com and a replay will be available until March 2, 2021.

About Cimpress

Cimpress plc (Nasdaq: CMPR) invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization is a competitive strategy which seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Cimpress businesses include BuildASign, Drukwerkdeal, Exaprint, National Pen, Pixartprinting, Printi, Vistaprint and WIRmachenDRUCK. To learn more, visit http://www.cimpress.com.

Cimpress and the Cimpress logo are trademarks of Cimpress plc or its subsidiaries. All other brand and product names appearing on this announcement may be trademarks or registered trademarks of their respective holders.

Investor Relations:

Meredith Burns

[email protected]

+1.781.652.6480

Media Relations:

Paul McKinlay

[email protected]

KEYWORDS: Europe Ireland United States North America Massachusetts

INDUSTRY KEYWORDS: Other Communications Finance Consulting Marketing Advertising Communications Professional Services Small Business Other Professional Services

MEDIA:

Fulton Bank, N.A. Purchases the Outstanding Stock of BenefitWorks

Fulton Bank, N.A. Purchases the Outstanding Stock of BenefitWorks

LANCASTER, Pa.–(BUSINESS WIRE)–
Fulton Bank, N.A., a subsidiary of Fulton Financial Corporation (NASDAQ: FULT) based in Lancaster, PA, today announced that it has acquired all outstanding stock of BenefitWorks, Inc., a registered investment advisor and retirement services firm in central Pennsylvania. The transaction was completed on November 20, 2020. The terms of the agreement have not been disclosed.

BenefitWorks is located in Lebanon, PA. The company was founded more than 35 years ago as Trefsgar & Co., later changing its name to BenefitWorks, Inc. in 2007. The firm specializes in investment advisory services and qualified retirement plan recordkeeping for companies, organizations and individuals throughout the mid-Atlantic region. BenefitWorks had approximately $177 million in assets under management or administration as of September 30, 2020. Fulton Bank has approximately $12 billion in assets under management or administration through its wealth and investment management division, Fulton Financial Advisors.

“Through our acquisition of BenefitWorks, Fulton will be able to reach and serve a greater number of clients in central Pennsylvania,” said Curtis Myers, Chairman and CEO of Fulton Bank. “We respect the business that Brooks Trefsgar and his team have built over the past 35 years and we share their focus on providing personalized financial solutions tailored to each unique client. We have been meeting with BenefitWorks’ clients to share what Fulton has to offer: outstanding service, a solid reputation and best-in-class products.”

“BenefitWorks is excited for our qualified plan clients and our individual investors. Plan sponsors, plan participants and individual investors will all benefit from familiar continued hands-on services and will be the beneficiaries of many Fulton enhancements,” said Brooks Trefsgar, President of BenefitWorks.

BenefitWorks will initially continue to operate as a separate subsidiary of Fulton Bank and, over the next several quarters, BenefitWorks clients will be transitioned to the Fulton Financial Advisors platform.

For more information about Fulton Bank, N.A. or its wealth and investment management division, Fulton Financial Advisors, visit www.fultonbank.com or www.fultonfinancialadvisors.com.

Securities and Insurance products are not a deposit or other obligation of, or guaranteed by Fulton Bank or any affiliate of the bank; are not insured by the FDIC or any other state or federal government agency, the bank or an affiliate of the bank; and are subject to investment risk, including the possible loss of value.

Media Contact: Laura J. Wakeley, 717-291-2616

Investor Contact: Mark McCollom, 717-327-2567

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Open Lending Signs OE Federal Credit Union to Lenders Protection™ Program

OE Federal Credit Union of California signs with Open Lending

AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) — Open Lending (NASDAQ: LPRO) provides loan analytics, risk-based pricing, risk modeling and default insurance to auto lenders throughout the United States. They announced today that OE Federal Credit Union, a $1.2 billion institution based in Livermore, CA, has signed with Open Lending to implement their Lenders Protection™ program.

OE Federal Credit Union is the country’s largest labor-based credit union, serving union members in the construction trades.  Gabriel Ybarrolaza, Vice President of Lending, explains, “Our members work long hours and are subject to seasonal work. OE Federal’s mission is to provide services to these members and their families. Open Lending allows us to expand auto lending that has historically been a challenge.”

Open Lending’s flagship product, Lenders Protection™, is a unique auto lending enablement platform. It utilizes proprietary data and advanced decisioning analytics to provide lenders with a powerful way to increase near and non-prime auto loan volumes, without adding significant risk to their auto loan portfolio. Lenders Protection™ allows auto lenders to model their specific overhead and funding costs and set a target ROA for their insured portfolio. The result is a profitable auto loan portfolio with carefully managed pricing and risk characteristics.

Matt Roe, Chief Revenue Officer at Open Lending, says, “We are honored to partner with OE Federal Credit Union. We know that the Lenders Protection™ program will help expand their auto lending offerings, ultimately supporting them in their mission to serve more members.”

About Open Lending
Open Lending (NASDAQ: LPRO) provides loan analytics, risk-based pricing, risk modeling and default insurance to auto lenders throughout the United States. For 20 years they have been empowering financial institutions to create profitable auto loan portfolios by saying “yes” to more automotive loans. For more information, please visit www.openlending.com.

OE
Federal
Credit Union

OE Federal was founded in 1964 in the union hall of Operating Engineers Local #3 with one simple goal: to provided union members a better alternative to banks. The union members needed a financial institution that understood the challenges of the construction trade. Today OE Federal serves over 125 union groups with more than 85,000 members nationwide. “OE Federal is here to help because we are union family, and our family deserves the best.”

Media Contact

Ginny Goertz | [email protected]



MP Materials Announces Financial Results for the Third Quarter and Year-To-Date Ended September 30, 2020

MP Materials Announces Financial Results for the Third Quarter and Year-To-Date Ended September 30, 2020

Third Quarter 2020 Revenue Grew 52% Year-Over-Year to $41.0 Million

Net Income Increased 4.2x Year-Over-Year to $14.6 Million

Adjusted EBITDA Grew 159% Year-Over-Year to $11.6 million

MOUNTAIN PASS, Calif.–(BUSINESS WIRE)–
MP Materials Corp. (NYSE: MP) (“MP Materials” or the “Company”), the largest rare earth materials producer in the Western Hemisphere, today announced its financial results for the third quarter and year-to-date ended September 30, 2020. A more detailed review of the year-to-date results can be found in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission today.

“Our results show continued strong operational execution throughout 2020,” said James Litinsky, Chairman and Chief Executive Officer of MP Materials. “With our business combination complete, MP has a fully equitized balance sheet to support the execution of our long-term plans to become a key supply chain partner as global industry advances towards electrification,” added Litinsky. “Our next several quarters will be focused on our move downstream into production of higher-margin separated rare earths with a focus on NdPr. We expect to continue driving profitable growth as we produce our rare earth concentrate, which comprises 15% of global rare earth content today.”

Recent Business Highlights

  • Completed its Business Combination with Fortress Value Acquisition Corp. on November 17, 2020, resulting in the listing of MP Materials shares on the New York Stock Exchange under the symbol “MP”
  • Through the business combination and related PIPE transaction, MP Materials raised $545 million to fully fund its three-stage business plan to restore the full rare earth materials supply chain to the U.S., closing a critical defense and economic security gap
  • On November 17, 2020, the Department of Defense (“DoD”) announced that MP Materials was awarded a Defense Production Act Title III technology investment agreement, which includes a $9.6 million DoD contribution to MP’s Stage II optimization
  • Completed front-end engineering design (FEED) and all circuit designs for Stage II optimization

Q3 Financial and Operating Highlights

  • Third quarter revenue increased 52% year-over-year, to $41.0 million, driven primarily by higher realized pricing and inclusive of an $8.9 million tariff refund received
  • Adjusted EBITDA for the third quarter of 2020 increased 159% year-over-year to $11.6 million; the Adjusted EBITDA calculation excludes the $8.9 million benefit from the tariff refund
  • In the third quarter, MP produced 10,197 metric tons of contained rare earth oxide (“REO”) in concentrate, higher both year-over-year and sequentially; production cost of $1,389 per metric ton of REO was down modestly on a sequential basis
  • MP sold 9,429 metric tons of REO in the quarter at an average realized price of $3,393 per metric ton; higher realized pricing was driven by higher market prices and the lifting of certain import duties; sold volumes fluctuate quarter to quarter based on production and shipment timing and MP continues to foresee 100% sell through of its production

Third Quarter and Year-To-Date 2020 Financial Results

 
 
MP MINE OPERATIONS LLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three months ended Nine months ended
(Unaudited) September 30, September 30,

 

2020

 

 

2019

 

 

2020

 

 

2019

 

(in thousands)
Product Sales (including sales to related parties)

$

41,022

 

$

26,916

 

$

92,132

 

$

52,363

 

Operating costs and expenses (excluding one-time settlement charge)

 

(24,868

)

 

(25,008

)

 

(67,961

)

 

(61,597

)

One-time settlement charge

 

 

 

 

 

(66,615

)

 

 

Operating Income/(Loss)

 

16,154

 

 

1,908

 

 

(42,444

)

 

(9,234

)

Other income, net

 

61

 

 

1,729

 

 

298

 

 

4,114

 

Interest expense

 

(1,713

)

 

(825

)

 

(3,582

)

 

(2,671

)

Income/(Loss) before income taxes

 

14,502

 

 

2,812

 

 

(45,728

)

 

(7,791

)

Income tax benefit/(expense)

 

125

 

 

 

 

(211

)

 

(1

)

Net Income/(Loss)

$

14,627

 

$

2,812

 

$

(45,939

)

$

(7,792

)

 
 
MP MINE OPERATIONS LLC
RECONCILIATION OF NET INCOME/(LOSS) TO ADJUSTED EBITDA
(Unaudited) Three months ended Six months ended Nine months ended
September 30, June 30, September 30,

 

2020

 

 

2019

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

(in thousands)
Net Income/(Loss)

$

14,627

 

$

2,812

 

$

(60,566

)

$

(10,604

)

$

(45,939

)

$

(7,792

)

Adjusted for:
Depreciation, depletion and amortization

 

2,179

 

 

1,356

 

 

2,653

 

 

2,379

 

 

4,832

 

 

3,735

 

Interest expense

 

1,713

 

 

825

 

 

1,869

 

 

1,846

 

 

3,582

 

 

2,671

 

Income tax expense/(benefit)

 

(125

)

 

 

 

336

 

 

1

 

 

211

 

 

1

 

Transaction-related costs1

 

80

 

 

 

 

1,572

 

 

 

 

1,652

 

 

 

Accretion of ARO and environmental reserves

 

563

 

 

526

 

 

1,128

 

 

1,051

 

 

1,691

 

 

1,577

 

Other non-recurring costs2

 

479

 

 

125

 

 

259

 

 

125

 

 

738

 

 

250

 

Royalties to SNR3

 

1,055

 

 

564

 

 

853

 

 

521

 

 

1,908

 

 

1,085

 

One-time settlement charge4

 

 

 

 

 

66,615

 

 

 

 

66,615

 

 

 

Tariff credits5

 

(8,901

)

 

 

 

(1,446

)

 

 

 

(10,347

)

 

 

Other income, net6

 

(61

)

 

(1,729

)

 

(237

)

 

(2,385

)

 

(298

)

 

(4,114

)

Adjusted EBITDA

$

11,609

 

$

4,479

 

$

13,036

 

$

(7,066

)

$

24,645

 

$

(2,587

)

 
 
  1. Includes mainly advisory, consulting, accounting and legal expenses in connection with the business combination.

  2. Includes mainly non-recurring costs for SAP implementation in the three and nine months ended September 30, 2020 and, in 2019, one-time severance payments to certain former members of our executive team.
  3. Our royalty payments to SNR will be eliminated upon the consummation of the business combination. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Recent Developments and Comparability of Results—The Business Combination” in our Current Report on Form 8-K filed on November 23, 2020.
  4. One-time settlement charge in connection with the termination of the Distribution and Marketing Agreement entered into with Leshan Shenghe Rare Earth Co., Ltd. in 2017. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Recent Developments and Comparability of Results—Our Relationship with Shenghe.” in our Current Report on Form 8-K filed on November 23, 2020.
  5. Represents non-cash revenue recognized in connection with tariff credits received from Shenghe Resources (Singapore) relating to product sales prior to May 2020, which is removed from Adjusted EBITDA to reflect the out-of-period income recognized without their related costs. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Recent Developments and Comparability of Results— Certain Tariff-related Rebates.” in our Current Report on Form 8-K filed on November 23, 2020.
  6. Includes mainly a mix of gains on sale of idle mining equipment following the 2017 acquisition of Mountain Pass and interest income on restricted cash.

Conference Call Details

MP Materials will host a conference call to discuss these results at 8:30 a.m. Eastern Time tomorrow, Tuesday, November 24, 2020. To access the conference call, participants should dial (833) 350-1335 and international participants should dial (236) 389-2432 and enter the conference ID number 5090136. The live audio webcast along with the press release and accompanying slide presentation, will be accessible on the Company’s Investor Relations website at investors.mpmaterials.com. A recording of the webcast will also be available following the conference call.

About MP Materials

MP Materials Corp. (NYSE: MP) is the largest producer of rare earth materials in the Western Hemisphere. With over 270 employees, the Company owns and operates Mountain Pass, an iconic American industrial asset, which is the only rare earth mining and processing site of scale in the Western Hemisphere and currently produces approximately 15% of global rare earth content. Separated rare earth elements are critical inputs for the magnets that enable the mobility of electric vehicles, drones, defense systems, wind turbines, robotics and many other high-growth, advanced technologies. MP Materials’ integrated operations at Mountain Pass uniquely combine low production costs with best-in-class environmental standards, thereby restoring American leadership to a critical industry with a strong commitment to sustainability. More information is available at https://mpmaterials.com/.

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “target,” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of MP Materials’ management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of MP Materials. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the business combination; risks relating to the uncertainty of the projected financial information with respect to MP Materials; risks related to the rollout of MP Materials’ business strategy and the timing of expected business milestones; risks related to MP Materials’ arrangements with Shenghe; the effects of competition on MP Materials’ future business; risks related to political and macroeconomic uncertainty; the impact of the global COVID-19 pandemic on any of the foregoing risks; and those factors discussed in MP Materials’ Current Report on Form 8-K filed on November 23, 2020 and Fortress Value Acquisition Corp.’s (n/k/a MP Materials) definitive proxy statement/consent solicitation/prospectus filed on October 27, 2020 under the heading “Risk Factors,” and other documents to be filed by MP Materials, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that MP Materials does not presently know or that MP Materials currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect MP Materials’ expectations, plans or forecasts of future events and views as of the date of this press release. MP Materials anticipates that subsequent events and developments will cause MP Materials’ assessments to change. However, while MP Materials may elect to update these forward looking statements at some point in the future, MP Materials specifically disclaims any obligation to do so, unless required by applicable law. These forward-looking statements should not be relied upon as representing MP Materials’ assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Use of Non-GAAP Financial Measures

This press release references certain non-GAAP financial measures, including Adjusted EBITDA. EBITDA is defined as net earnings (loss) before interest expense, income tax expense (benefit), depreciation, depletion and amortization. Adjusted EBITDA is defined as EBITDA further adjusted to eliminate the impact of transaction-related costs, other non-recurring costs, royalty payments to SNR, tariff credits, accretion of asset retirement obligations and environmental reserves and gain on sale or disposal of long-lived assets. MP Materials’ management uses Adjusted EBITDA and other non-GAAP measures to compare MP Materials’ performance to that of prior periods for trend analyses and for budgeting and planning purposes. MP Materials believes Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to MP Materials’ financial condition and results of operations. MP Materials believes that the use of Adjusted EBITDA provides an additional tool for investors to use in evaluating projected operating results and trends. MP Materials’ method of determining these non-GAAP measures may be different from other companies’ methods and, therefore, may not be comparable to those used by other companies and MP Materials does not recommend the sole use of these non-GAAP measures to assess its financial performance. Management does not consider non-GAAP measures in isolation or as an alternative or to be superior to financial measures determined in accordance with GAAP. The principal limitation of non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in MP Materials’ financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. In order to compensate for these limitations, management presents reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures.

Investors:

Ellipsis

Jeff Majtyka / Taylor Krafchik

[email protected]

Media:

Edelman

Jordan Fisher

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Natural Resources Other Natural Resources Mining/Minerals

MEDIA:

Logo
Logo

Neuronetics® Receives FDA Clearance for Three-Minute TouchStar™ Treatment Protocol

TouchStar theta burst protocol leverages NeuroStar® Advanced Therapy’s patented Contact Sensing technology to help ensure the optimum prescribed treatment dose to patients

MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced the U.S. Food and Drug Administration (FDA) granted clearance for the Company’s TouchStar treatment, a three-minute intermittent theta burst (iTBS) protocol with its NeuroStar Advanced Therapy System, administered with patented Contact Sensing technology.

The new protocol arms physicians with the ability to now offer a third FDA-cleared treatment protocol with NeuroStar Advanced Therapy – a non-drug, non-invasive transcranial magnetic stimulation (TMS) treatment for Major Depressive Disorder (MDD) that uses magnetic pulses to stimulate areas of the brain that are underactive in depression. The three-minute TouchStar protocol allows clinicians to further customize treatments to best suit patient needs while increasing utilization of the NeuroStar Advanced Therapy System and expanding its benefits to more patients.

TouchStar with Contact Sensing provides physicians and their patients with the option of shorter treatment sessions using higher frequency pulses while helping ensure that the proper dose is being given at every session. The Contact Sensing technology monitors NeuroStar Advanced Therapy’s contoured coil, which is designed with a curve to fit the head and provides continuous real-time feedback about the coil’s angle and contact with the head.

“The TouchStar protocol is particularly impactful when paired with our patented Contact Sensing precision technology that provides clinicians with the confidence of knowing they are giving patients the right dose at the exact location,” said Greg Harper, Vice President of Product Development and Operations at Neuronetics. “A faster solution to target depression is certainly a benefit, but when we’re shortening those treatment times it is even more critical that proper coil position is maintained. With TMS systems, if coil contact with the head is off by just 1mm, up to 40 percent of the required dosage can be lost1 – Contact Sensing monitors coil position and helps ensure patients get the full prescribed treatment dosage every session.”

TouchStar is the latest advancement designed to enhance treatment options and expand access and availability of NeuroStar Advanced Therapy for patients. The system now has three treatment variations: standard, which offers treatments at 37.5 minutes per session; DASH, which offers treatments as little as 19 minutes per session; and TouchStar, which offers treatments at three minutes per session. TouchStar will be available to NeuroStar providers in the first quarter of 2021.

“TouchStar protocol clearance is an especially relevant milestone as depression rates continue to rise and providing access to proven depression treatments remains more critical than ever before,” said Keith J. Sullivan, President and CEO of Neuronetics. “Our hope is that this third treatment protocol will mean even more patients in need will have access to NeuroStar Advanced Therapy to help them in their battle with this debilitating disease.”

Neuronetics remains committed to gathering real world outcomes for treatment through the NeuroStar Outcomes Registry and will include TouchStar data as part of the largest outcomes registry in the world for MDD. Visit www.neurostar.com for more information.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com.

Media Contact:

Meagan Dominick
Vault Communications
610-455-2779
[email protected]

1 Data on file. Neuronetics, Inc.



PPG Introduces PPG ENVIROCRON HeatSense Powder Coating for Heat-sensitive Wood, Composite Applications

PPG Introduces PPG ENVIROCRON HeatSense Powder Coating for Heat-sensitive Wood, Composite Applications

New coating complements latest advances in low-temperature cure technology

PITTSBURGH–(BUSINESS WIRE)–
PPG (NYSE:PPG) today announced the introduction of PPG ENVIROCRON™ HeatSense powder coating for heat-sensitive wood and wood-composite applications, such as medium-density fiberboard (MDF), hardwood, plywood and similar products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201123006252/en/

PPG Envirocron HeatSense creates design freedom and valuable benefits in the office furniture market, including sealed edges that improve moisture resistance and increase longevity of the pieces.

PPG Envirocron HeatSense creates design freedom and valuable benefits in the office furniture market, including sealed edges that improve moisture resistance and increase longevity of the pieces.

Engineered to complement the latest advances in low-temperature cure technology, PPG Envirocron HeatSense coating is formulated to overcome the barriers that have traditionally prevented powder coatings from being a viable option for the wood-finish market. The coating can cure in as few as five minutes at 250 degrees Fahrenheit, be applied uniformly over heat-sensitive substrates and accommodate the shrinking and swelling of wood over the finished product’s lifetime.

The coating encapsulates the substrate with a smooth, durable finish, providing a moisture barrier and allowing freedom of design not possible with laminated coatings. When applied and cured properly, PPG Envirocron HeatSense coating enables wood manufacturers to finish their products in a broad range of colors, textures, special effects and antimicrobial*-protected coating options, such as PPG SILVERSAN® coatings.

Used in a one- or two-coat process, PPG Envirocron HeatSense coating can be cured quickly in a convection or infrared (IR) oven and is fully reclaimable, allowing for cost-effective and efficient production. In addition, the coating is formulated without volatile organic compounds (VOCs) and hazardous materials. It has an overall low carbon footprint when compared to solvent-based paints, stains and laminates.

“Powder coatings have long been valued on metal substrates for their durability and low carbon footprint,” said Shelley Verdun, PPG business manager, powder, industrial coatings. “The introduction of PPG Envirocron HeatSense coating enables us to transfer those benefits to key wood coating markets, such as cabinetry, office furniture and building products. It is a game changer for the industry, and PPG is excited to be the innovation leader.”

For more information about PPG Envirocron HeatSense coatings, visit www.ppgindustrialcoatings.com, connect with PPG on LinkedIn or call 1-800-258-6398.

*Antimicrobial is limited to the treated surface to provide mold and mildew resistance on the paint film and to inhibit the growth of stain and odor-causing bacteria that may affect the surface of the coating. The use of these products does not protect users of any such treated article or others against food-borne or disease-causing bacteria, viruses, germs or other disease-causing organisms.

PPG: WE PROTECT AND BEAUTIFY THE WORLD™

At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for 135 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $15.1 billion in 2019. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.

We protect and beautify the world and Envirocron are trademarksand SilverSan and the PPG Logo are registered trademarks of PPG Industries Ohio, Inc.

CATEGORY Industrial Coatings

Desiree Miller

Industrial Coatings

+1 412-508-2261

[email protected]

www.ppgindustrialcoatings.com

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Packaging Chemicals/Plastics Manufacturing

MEDIA:

Logo
Logo
Photo
Photo
PPG Envirocron HeatSense creates design freedom and valuable benefits in the office furniture market, including sealed edges that improve moisture resistance and increase longevity of the pieces.

NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference

BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference on December 1st.

An audio webcast of the pre-recorded fireside chat will be available through the Investors section of the company’s website at www.nextcure.com and archived on the website for 30 days.

About NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.com

Cautionary Statement Regarding Forward-Looking Statements

Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.



Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
[email protected]